FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Pennington

Research Profile

Chemicals & Drugs

Genes & Molecular Sequences

Amino Acid Sequences

Concepts & Ideas

Co-author Network

Publications

TOP 3
Michael Pennington; Rajeev B Tajhya; Christine Beeton; M Harunur Rashid; Serdar Kuyucak; Raymond S Norton
A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3.
Shih Chieh Chang; Charles Galea; Eleanor W W Leung; Michael Pennington; Rajeev B Tajhya; Christine Beeton; Raymond S Norton
Expression and isotopic labelling of the potassium channel blocker ShK toxin as a thioredoxin fusion protein in bacteria.
Eric J Tarcha; Indra Tjong; Sanjeev K Upadhyay; David Bailey; Amy Banks; Christine Beeton; Scott E Boley; K George Chandy; Victor Chi; Zachary Hansen; Xueyou Hu; Dustin Kentala; Brian Knapp; Luz M Londono; Ernesto J Muñoz-Elías; Hai Nguyen; Kayla Norton; Michael Pennington; Greg W Ruppert; James Sams; Richard Slauter; Shawn P Iadonato
Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Pennington (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Michael Pennington; Rajeev B Tajhya; Christine Beeton; M Harunur Rashid; Serdar Kuyucak; Raymond S Norton
A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3.
FEBS letters 2012;586(22):3996-4001.
2012: Shih Chieh Chang; Charles Galea; Eleanor W W Leung; Michael Pennington; Rajeev B Tajhya; Christine Beeton; Raymond S Norton
Expression and isotopic labelling of the potassium channel blocker ShK toxin as a thioredoxin fusion protein in bacteria.
Toxicon : official journal of the International Society on Toxinology 2012;60(5):840-50.
2012: Eric J Tarcha; Indra Tjong; Sanjeev K Upadhyay; David Bailey; Amy Banks; Christine Beeton; Scott E Boley; K George Chandy; Victor Chi; Zachary Hansen; Xueyou Hu; Dustin Kentala; Brian Knapp; Luz M Londono; Ernesto J Muñoz-Elías; Hai Nguyen; Kayla Norton; Michael Pennington; Greg W Ruppert; James Sams; Richard Slauter; Shawn P Iadonato
Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.
The Journal of pharmacology and experimental therapeutics 2012;342(3):642-53.
2012: Victor Chi; Shawn Iadonato; Jonathan T Lakey; Luz M Londono; Raymond S Norton; Michael Pennington; Brian Sims-Fahey; Eric J Tarcha; Sanjeev K Upadhyay; Heike Wulff; Christine Beeton; K George Chandy
Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases.
Toxicon : official journal of the International Society on Toxinology 2012;59(4):529-46.
2011: Christine Beeton; Michael Pennington; Raymond S Norton
Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.
Inflammation & allergy drug targets 2011;10(5):313-21.
2010: srikant rangaraju; Keith K Khoo; Zhi-Ping Feng; George Crossley; Daniel Nugent; Ilya Khaytin; Victor Chi; Cory Pham; Peter A Calabresi; Michael Pennington; Raymond S Norton; K George Chandy
Potassium channel modulation by a toxin domain in matrix metalloprotease 23.
The Journal of biological chemistry 2010;285(12):9124-36.
2009: srikant rangaraju; Victor Chi; Michael Pennington; K George Chandy
Kv1.3 potassium channels as a therapeutic target in multiple sclerosis.
Expert opinion on therapeutic targets 2009;13(8):909-24.
2009: Michael Pennington; Christine Beeton; Charles Galea; B J Smith; V Chi; K P Monaghan; A Garcia; srikant rangaraju; A Giuffrida; D Plank; G Crossley; D Nugent; I Khaytin; Y Lefievre; I Peshenko; C Dixon; S Chauhan; A Orzel; T Inoue; X Hu; R V Moore; R S Norton; K G Chandy
Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes.
Molecular pharmacology 2009;75(4):762-73.
2009: Satendra S Chauhan; A Varshney; B Verma; Michael Pennington
Efficient synthesis of protected L-phosphonophenylalanine (Ppa) derivatives suitable for solid phase synthesis.
Advances in experimental medicine and biology 2009;611():191-2.
2008: Melanie P Matheu; Christine Beeton; Adriana Garcia; Victor Chi; srikant rangaraju; Olga Safrina; Kevin Monaghan; Marc I Uemura; Dan Li; Sukumar Pal; Luis M de la Maza; Edwin Monuki; Alexander Flügel; Michael Pennington; Ian Parker; K George Chandy; Michael D Cahalan
Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block.
Immunity 2008;29(4):602-14.
2008: Christine Beeton; Brian J Smith; Jennifer K Sabo; George Crossley; Daniel Nugent; Ilya Khaytin; Victor Chi; K George Chandy; Michael Pennington; Raymond S Norton
The D-diastereomer of ShK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation.
The Journal of biological chemistry 2008;283(2):988-97.
2007: Jacques A Durr; Mary Blankenship; Satendra S Chauhan; Michael Pennington
Targeted tyrosine iodination in a multi-tyrosine vasopressin analog.
Journal of peptide science : an official publication of the European Peptide Society 2007;13(11):756-61.
2007: Lina Hu; Michael Pennington; Qiong Jiang; Katharine A Whartenby; Peter A Calabresi
Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 2007;179(7):4563-70.
2007: Heike Wulff; Michael Pennington
Targeting effector memory T-cells with Kv1.3 blockers.
Current opinion in drug discovery & development 2007;10(4):438-45.
2006: Christine Beeton; Heike Wulff; Nathan E Standifer; Philippe Azam; Katherine M Mullen; Michael Pennington; Aaron Kolski-Andreaco; Eric Wei; Alexandra Grino; Debra R Counts; Ping H Wang; Christine J LeeHealey; Brian S Andrews; Ananthakrishnan Sankaranarayanan; Daniel Homerick; Werner W Roeck; Jamshid Tehranzadeh; Kimber L Stanhope; Pavel Zimin; Peter J Havel; Stephen M Griffey; Hans-Günther Knaus; Gerald Nepom; George A Gutman; Peter A Calabresi; K George Chandy
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(46):17414-9.
2006: Katherine M Mullen; Monika Rozycka; Horea Rus; Lina Hu; Cornelia Cudrici; Ekaterina Zafranskaia; Michael Pennington; David C Johns; Susan I V Judge; Peter A Calabresi
Potassium channels Kv1.3 and Kv1.5 are expressed on blood-derived dendritic cells in the central nervous system.
Annals of neurology 2006;60(1):118-27.
2005: Christine Beeton; Michael Pennington; Heike Wulff; Satendra Singh; Daniel Nugent; George Crossley; Ilya Khaytin; Peter A Calabresi; Chao Chen; George A Gutman; K George Chandy
Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.
Molecular pharmacology 2005;67(4):1369-81.
2005: Xavier Lauth; jeffrey babon; Jason A Stannard; Satendra Singh; Victor Nizet; James M Carlberg; Vaughn E Ostland; Michael Pennington; Raymond S Norton; Mark E Westerman
Bass hepcidin synthesis, solution structure, antimicrobial activities and synergism, and in vivo hepatic response to bacterial infections.
The Journal of biological chemistry 2005;280(10):9272-82.
2004: Raymond S Norton; Michael Pennington; Heike Wulff
Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases.
Current medicinal chemistry 2004;11(23):3041-52.
2004: Heike Wulff; Hans-Günther Knaus; Michael Pennington; K George Chandy
K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity.
Journal of immunology (Baltimore, Md. : 1950) 2004;173(2):776-86.
2004: Satendra Singh; Samala J Rao; Michael Pennington
Efficient asymmetric synthesis of (S)- and (R)-N-Fmoc-S-trityl-alpha-methylcysteine using camphorsultam as a chiral auxiliary.
The Journal of organic chemistry 2004;69(13):4551-4.
2004: K George Chandy; Heike Wulff; Christine Beeton; Michael Pennington; George A Gutman; Michael D Cahalan
K+ channels as targets for specific immunomodulation.
Trends in pharmacological sciences 2004;25(5):280-9.
2004: Stephen F Brady; Satendra Singh; Ming-Chih Crouthamel; M Katharine Holloway; Craig A Coburn; Victor M Garsky; Michael J Bogusky; Michael Pennington; Joseph P Vacca; Daria J Hazuda; Ming-Tain Lai
Rational design and synthesis of selective BACE-1 inhibitors.
Bioorganic & medicinal chemistry letters 2004;14(3):601-4.
2003: Alexei F Kisselev; Margarita Garcia-Calvo; Herman S Overkleeft; Erin Peterson; Michael Pennington; Hidde L Ploegh; Nancy A Thornberry; Alfred L Goldberg
The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites.
The Journal of biological chemistry 2003;278(38):35869-77.
2003: Heike Wulff; Peter A Calabresi; Rameeza Allie; Sung Yun; Michael Pennington; Christine Beeton; K George Chandy
The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS.
The Journal of clinical investigation 2003;111(11):1703-13.
2003: Christine Beeton; Heike Wulff; Satendra Singh; Steve Botsko; George Crossley; George A Gutman; Michael D Cahalan; Michael Pennington; K George Chandy
A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes.
The Journal of biological chemistry 2003;278(11):9928-37.
2002: Mark D Lanigan; Katalin Kalman; Yann Lefievre; Michael Pennington; K George Chandy; Raymond S Norton
Mutating a critical lysine in ShK toxin alters its binding configuration in the pore-vestibule region of the voltage-gated potassium channel, Kv1.3.
Biochemistry 2002;41(40):11963-71.
2001: Mark D Lanigan; Michael Pennington; Y Lefievre; H Rauer; Raymond S Norton
Designed peptide analogues of the potassium channel blocker ShK toxin.
Biochemistry 2001;40(51):15528-37.
2001: Christine Beeton; Heike Wulff; Jocelyne Barbaria; O Clot-Faybesse; Michael Pennington; Dominique Bernard; Michael D Cahalan; K George Chandy; Evelyne Béraud
Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(24):13942-7.
2001: K G Chandy; Michael D Cahalan; Michael Pennington; Raymond S Norton; Heike Wulff; George A Gutman
Potassium channels in T lymphocytes: toxins to therapeutic immunosuppressants.
Toxicon : official journal of the International Society on Toxinology 2001;39(9):1269-76.
2001: Mark D Lanigan; J E Tudor; Michael Pennington; Raymond S Norton
A helical capping motif in ShK toxin and its role in helix stabilization.
Biopolymers 2001;58(4):422-36.
2000: H Rauer; Mark D Lanigan; Michael Pennington; J Aiyar; S Ghanshani; Michael D Cahalan; Raymond S Norton; K George Chandy
Structure-guided transformation of charybdotoxin yields an analog that selectively targets Ca(2+)-activated over voltage-gated K(+) channels.
The Journal of biological chemistry 2000;275(2):1201-8.
1999: Michael Pennington; Mark D Lanigan; Katalin Kalman; Vladimir M Mahnir; H Rauer; C T McVaugh; D Behm; D Donaldson; K George Chandy; William R Kem; Raymond S Norton
Role of disulfide bonds in the structure and potassium channel blocking activity of ShK toxin.
Biochemistry 1999;38(44):14549-58.
1999: H Rauer; Michael Pennington; Michael D Cahalan; K George Chandy
Structural conservation of the pores of calcium-activated and voltage-gated potassium channels determined by a sea anemone toxin.
The Journal of biological chemistry 1999;274(31):21885-92.
1999: Todd R Pray; Anson M Nomura; Michael Pennington; Charles S Craik
Auto-inactivation by cleavage within the dimer interface of Kaposi's sarcoma-associated herpesvirus protease.
Journal of molecular biology 1999;289(2):197-203.
1999: Ben M Dunn; Michael Pennington; D C Frase; K Nash
Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem.
Biopolymers 1999;51(1):69-77.
1998: Katalin Kalman; Michael Pennington; Mark D Lanigan; A Nguyen; H Rauer; Vladimir M Mahnir; K Paschetto; William R Kem; Stephan Grissmer; George A Gutman; E P Christian; Michael D Cahalan; Raymond S Norton; K George Chandy
ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide.
The Journal of biological chemistry 1998;273(49):32697-707.
1998: J E Tudor; Michael Pennington; Raymond S Norton
Ionisation behaviour and solution properties of the potassium-channel blocker ShK toxin.
European journal of biochemistry / FEBS 1998;251(1-2):133-41.
1997: A Unal; Todd R Pray; Michael Lagunoff; Michael Pennington; Don Ganem; Charles S Craik
The protease and the assembly protein of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8).
Journal of virology 1997;71(9):7030-8.
1996: Michael Pennington; Vladimir M Mahnir; I Khaytin; I Zaydenberg; M E Byrnes; William R Kem
An essential binding surface for ShK toxin interaction with rat brain potassium channels.
Biochemistry 1996;35(51):16407-11.
1996: J E Tudor; Paul K Pallaghy; Michael Pennington; Raymond S Norton
Solution structure of ShK toxin, a novel potassium channel inhibitor from a sea anemone.
Nature structural biology 1996;3(4):317-20.
1996: Michael Pennington; Vladimir M Mahnir; D S Krafte; I Zaydenberg; M E Byrnes; I Khaytin; K Crowley; William R Kem
Identification of three separate binding sites on SHK toxin, a potent inhibitor of voltage-dependent potassium channels in human T-lymphocytes and rat brain.
Biochemical and biophysical research communications 1996;219(3):696-701.
1996: T R Dyke; Brendan Duggan; Michael Pennington; M E Byrnes; William R Kem; Raymond S Norton
Synthesis and structural characterisation of analogues of the potassium channel blocker charybdotoxin.
Biochimica et biophysica acta 1996;1292(1):31-8.
1995: Michael Pennington; M E Byrnes; I Zaydenberg; I Khaytin; J de Chastonay; D S Krafte; R Hill; Vladimir M Mahnir; W A Volberg; W Gorczyca
Chemical synthesis and characterization of ShK toxin: a potent potassium channel inhibitor from a sea anemone.
International journal of peptide and protein research 1995;46(5):354-8.
1995: B P Holskin; M Bukhtiyarova; B M Dunn; P Baur; J de Chastonay; Michael Pennington
A continuous fluorescence-based assay of human cytomegalovirus protease using a peptide substrate.
Analytical biochemistry 1995;227(1):148-55.
1995: Michael Pennington; M E Byrnes
Evaluation of TiCl4-mediated reduction of methionine sulfoxide in peptides with oxidizable or reducible residues.
Peptide research 1995;8(1):39-43.
1994: Michael Pennington; I Zadenberg; M E Byrnes; Raymond S Norton; William R Kem
Synthesis of the cardiac inotropic polypeptide anthopleurin-A.
International journal of peptide and protein research 1994;43(5):463-70.
1994: Michael Pennington; N A Thornberry
Synthesis of a fluorogenic interleukin-1 beta converting enzyme substrate based on resonance energy transfer.
Peptide research 1994;7(2):72-6.
1994: Michael Pennington
HF cleavage and deprotection procedures for peptides synthesized using a Boc/Bzl strategy.
Methods in molecular biology (Clifton, N.J.) 1994;35():41-62.
1994: Michael Pennington
Solid-phase synthesis of peptides containing the CH2NH reduced bond surrogate.
Methods in molecular biology (Clifton, N.J.) 1994;35():241-7.
1994: Michael Pennington
Solid-phase synthesis of phosphorylated Tyr-peptides by "phosphite triester" phosphorylation.
Methods in molecular biology (Clifton, N.J.) 1994;35():195-200.
1994: Michael Pennington
Site-specific chemical modification procedures.
Methods in molecular biology (Clifton, N.J.) 1994;35():171-85.
1994: Michael Pennington; M E Byrnes
Procedures to improve difficult couplings.
Methods in molecular biology (Clifton, N.J.) 1994;35():1-16.
1993: Paul K Pallaghy; Brendan Duggan; Michael Pennington; Raymond S Norton
Three-dimensional structure in solution of the calcium channel blocker omega-conotoxin.
Journal of molecular biology 1993;234(2):405-20.
1993: P Chandler; Michael Pennington; M L Maccecchini; N T Nashed; Phil Skolnick
Polyamine-like actions of peptides derived from conantokin-G, an N-methyl-D-aspartate (NMDA) antagonist.
The Journal of biological chemistry 1993;268(23):17173-8.
1992: Phil Skolnick; K Boje; R Miller; Michael Pennington; M L Maccecchini
Noncompetitive inhibition of N-methyl-D-aspartate by conantokin-G: evidence for an allosteric interaction at polyamine sites.
Journal of neurochemistry 1992;59(4):1516-21.
1992: Michael Pennington; S M Festin; M L Maccecchini; William R Kem
Synthesis and characterization of a disulfide bond isomer of omega-conotoxin GVIA.
Toxicon : official journal of the International Society on Toxinology 1992;30(7):755-64.
1990: Michael Pennington; William R Kem; Raymond S Norton; Ben M Dunn
Chemical synthesis of a neurotoxic polypeptide from the sea anemone Stichodactyla helianthus.
International journal of peptide and protein research 1990;36(4):335-43.
1990: Michael Pennington; William R Kem; Ben M Dunn
Synthesis and biological activity of six monosubstituted analogs of a sea anemone polypeptide neurotoxin.
Peptide research 1990;3(5):228-32.
1989: William R Kem; B Parten; Michael Pennington; D A Price; Ben M Dunn
Isolation, characterization, and amino acid sequence of a polypeptide neurotoxin occurring in the sea anemone Stichodactyla helianthus.
Biochemistry 1989;28(8):3483-9.